Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CFTR | P13569 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA5A | P35218 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27728842 | 0.83 | HSP90AA1 (0.44) | HSP90AA1ALDH1A1USP2POLBKMT2A | |
| SCHEMBL3115111 | 0.83 | USP2 (0.47) | HSP90AA1ALDH1A1USP2POLBKMT2A | |
| Bromide SCHEMBL5222954 | 0.82 | USP2 (0.45) | HSP90AA1ALDH1A1USP2POLBKMT2A | |
| SCHEMBL7281507 | 0.82 | USP2 (0.45) | HSP90AA1ALDH1A1USP2POLBKMT2A | |
| SCHEMBL17064719 | 0.81 | ALDH1A1 (0.46) | HSP90AA1ALDH1A1USP2POLBKMT2A | |
| SCHEMBL5222945 | 0.80 | HSP90AA1 (0.42) | HSP90AA1ALDH1A1USP2POLBKMT2A | |
| SCHEMBL5593415 | 0.79 | POLB (0.54) | HSP90AA1ALDH1A1POLBKMT2AMEN1 | |
| Lithium Ion SCHEMBL7281502 | 0.78 | HSP90AA1 (0.41) | HSP90AA1ALDH1A1USP2KMT2AMEN1 | |
| SCHEMBL27646839 | 0.78 | HSP90AA1 (0.41) | HSP90AA1ALDH1A1USP2POLBKMT2A | |
| SCHEMBL10538450 | 0.78 | MAPT (0.48) | HSP90AA1ALDH1A1POLBKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130023551-A1 | DISPIRO TETRAOXANE COMPOUNDS | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2013-01-24 | — | — | US | disclosed |
| US-20100113436-A1 | DISPIRO TETRAOXANE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MALARIA AND/OR CANCER | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2010-05-06 | — | — | US | disclosed |
| US-20030236229-A1 | Novel 3,5,and/or 6 substituted analogues of swainsonine processes for their preparation and their use as therapeutic agents | GLYCODESIGN INC. (CA) | 2003-12-25 | — | — | US | disclosed |
| US-20020099065-A1 | Novel 3, 5, and/or 6 substituted analogues of swainsonine, processes for their preparation and their use as therapeutic agents | GLYCODESIGN INC. (CA) | 2002-07-25 | — | — | US | disclosed |
| US-6048870-A | MANNOSIDASE INHIBITOR; IMMUNOSTIMULANT | GLYCODESIGN (CA) | 2000-04-11 | — | — | US | disclosed |
| EP-0934318-A1 | NOVEL 3, 5, AND/OR 6 SUBSTITUTED ANALOGUES OF SWAINSONINE, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS THERAPEUTIC AGENTS | Glycodesign Inc. (CA) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998014446-A1 | NOVEL 3, 5, AND/OR 6 SUBSTITUTED ANALOGUES OF SWAINSONINE, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS THERAPEUTIC AGENTS | GLYCODESIGN INC. (CA) | 1998-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113436-A1 | DISPIRO TETRAOXANE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MALARIA AND/OR CANCER | NR1H2, NR1H3, NR1I2 | HSP90AA1 3635/4885ALDH1A1 2379/4885USP2 3102/4885 |
| US-20130023551-A1 | DISPIRO TETRAOXANE COMPOUNDS | NR1H3, NR1H2, NR1I2 | HSP90AA1 4402/4885ALDH1A1 2569/4885USP2 2627/4885 |
| US-20030236229-A1 | Novel 3,5,and/or 6 substituted analogues of swainsonine processes for their preparation and their use as therapeutic agents | WDR77, WDR3, WDR5 | HSP90AA1 1731/4885ALDH1A1 4618/4885USP2 2595/4885 |
| US-20020099065-A1 | Novel 3, 5, and/or 6 substituted analogues of swainsonine, processes for their preparation and their use as therapeutic agents | WDR5, WDR3, WDR77 | HSP90AA1 2526/4885ALDH1A1 4125/4885USP2 2857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.